Eli Lilly and Co (BUE:LLY) E10: ARS240.87 (As of Mar. 2026)


BUE:LLY Eli Lilly and Co BUE:LLY
97 GF Score
Price ARS33,240.00
GF Value ARS38,937.58
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Eli Lilly and Co E10?

Eli Lilly and Co BUE:LLY -2.52% 97 E10 is ARS240.87 as of Mar. 2026. GuruFocus rates BUE:LLY with a GF Score™ of 97/100 and a GF Value™ of ARS38,937.58 (Modestly Undervalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Eli Lilly and Co's adjusted earnings per share data for the three months ended in Mar. 2026 was ARS46,198.018. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is ARS240.87 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Eli Lilly and Co's average E10 Growth Rate was 43.10% per year. During the past 3 years, the average E10 Growth Rate was 19.10% per year. During the past 5 years, the average E10 Growth Rate was 14.30% per year. During the past 10 years, the average E10 Growth Rate was 10.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Eli Lilly and Co was 19.10% per year. The lowest was -2.70% per year. And the median was 5.90% per year.

As of today (2026-07-12), Eli Lilly and Co's current stock price is ARS33240.00. Eli Lilly and Co's E10 for the quarter that ended in Mar. 2026 was ARS240.87. Eli Lilly and Co's Shiller PE Ratio of today is 138.00.

During the past 13 years, the highest Shiller PE Ratio of Eli Lilly and Co was 172.05. The lowest was 23.03. And the median was 54.97.


Eli Lilly and Co  (BUE:LLY) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Eli Lilly and Co's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=33240.00/240.87
=138.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Eli Lilly and Co was 172.05. The lowest was 23.03. And the median was 54.97.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Eli Lilly and Co E10 Related Terms


Eli Lilly and Co E10 Historical Data

* Premium members only.

The historical data trend for Eli Lilly and Co's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eli Lilly and Co E10 Chart

Eli Lilly and Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 106.06 204.53 615.68 129.77 225.54

Eli Lilly and Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 150.37 151.52 208.70 225.54 240.87

BUE:LLY vs JNJ, ABBV, MRK: E10 Comparison

For the Drug Manufacturers - General subindustry, Eli Lilly and Co's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eli Lilly and Co Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Eli Lilly and Co's Shiller PE Ratio falls into.


BUE:LLY
97GF Score
Eli Lilly and Co BUE:LLY
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eli Lilly and Co E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Eli Lilly and Co's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=46198.018/330.2130*330.2130
=46,198.018

Current CPI (Mar. 2026) = 330.2130.

Eli Lilly and Co Quarterly Data

per share eps CPI Adj_EPS
201606 39.702 241.018 54.395
201609 43.557 241.428 59.575
201612 44.455 241.432 60.802
201703 -6.167 243.801 -8.353
201706 62.654 244.955 84.461
201709 37.150 246.819 49.702
201712 -120.680 246.524 -161.648
201803 93.491 249.554 123.708
201806 -24.940 251.989 -32.682
201809 164.860 252.439 215.652
201812 160.532 251.233 210.998
201903 673.912 254.202 875.424
201906 257.351 256.143 331.770
201909 306.474 256.759 394.151
201912 373.477 256.974 479.920
202003 397.244 258.115 508.204
202006 424.452 257.797 543.682
202009 394.957 260.280 501.076
202012 720.330 260.474 913.190
202103 536.877 264.877 669.306
202106 579.748 271.696 704.612
202109 477.166 274.310 574.410
202112 731.163 278.802 865.989
202203 901.925 287.504 1,035.907
202206 505.386 296.311 563.209
202209 894.838 296.808 995.550
202212 1,367.550 296.797 1,521.521
202303 1,177.398 301.836 1,288.091
202306 1,872.000 305.109 2,026.026
202309 -83.988 307.789 -90.107
202312 3,494.480 306.746 3,761.818
202403 8,357.600 312.332 8,836.072
202406 11,748.960 314.175 12,348.721
202409 4,068.140 315.301 4,260.541
202412 19,715.200 315.605 20,627.732
202503 13,048.292 319.799 13,473.199
202506 29,870.787 322.561 30,579.401
202509 33,733.028 324.800 34,295.211
202512 42,906.014 324.054 43,721.490
202603 46,198.018 330.213 46,198.018

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of ARS240.87 mean?
Eli Lilly and Co (BUE:LLY) has a E10 of ARS240.87 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Eli Lilly and Co and its competitors.
Is Eli Lilly and Co's E10 too high?
Eli Lilly and Co's current E10 is ARS240.87. Overall, Eli Lilly and Co has a GF Score™ of 97/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eli Lilly and Co's E10 compare to JNJ and ABBV?
Eli Lilly and Co's E10 of ARS240.87 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Drug Manufacturers company?
A good E10 depends on the Drug Manufacturers industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Eli Lilly and Co and its competitors. Eli Lilly and Co's current E10 is ARS240.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eli Lilly and Co stock overvalued right now?
Based on GuruFocus' analysis, Eli Lilly and Co (BUE:LLY) is currently considered Modestly Undervalued. The stock's GF Value™ is ARS38,937.58, compared to a current price of ARS33,240.00 — trading 14.6% below its estimated fair value. The current E10 is ARS240.87. Eli Lilly and Co's overall GF Score™ is 97/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Eli Lilly and Co (BUE:LLY), the current E10 is ARS240.87 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Eli Lilly and Co (BUE:LLY) Overvalued in 2026?

Based on GuruFocus' analysis, Eli Lilly and Co stock appears to be undervalued. The current stock price of ARS33,240.00 is trading 14.6% below its estimated GF Value™ of ARS38,937.58. GuruFocus considers Eli Lilly and Co to be Modestly Undervalued.

Key valuation signals for BUE:LLY:

  • E10: ARS240.87
  • GF Value™: ARS38,937.58 vs. price of ARS33,240.00 (14.6% below fair value)
  • GF Score™: 97/100 with 6 warning signs

No single metric tells the full story. See the BUE:LLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Eli Lilly and Co Business Description

Address Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
97GF Score

Get the complete analysis for BUE:LLY

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

ARS33,240.00
Price
ARS38,937.58
GF Value